Loading article
Conditions
What drives eczema flares, how the skin barrier theory changed treatment, and the evidence behind each management tier.
This article is for general information and does not constitute medical advice. Treatment decisions are made by an AHPRA-registered doctor after reviewing your circumstances.
Eczema is common, relapsing, and often misunderstood. Australian patient resources from healthdirect, ASCIA, and the Skin Health Institute describe it as a chronic inflammatory skin condition where the skin barrier does not hold moisture well, making skin more vulnerable to irritants, allergens, scratching, and infection.
Eczema (atopic dermatitis) is a chronic inflammatory skin condition characterised by skin barrier dysfunction, immune dysregulation, and heightened sensitivity to environmental triggers. It is not simply dry skin, and it is not contagious. With the right approach, most patients achieve sustained control - but understanding what drives the condition is essential for effective management.
Contemporary understanding of eczema centres on the skin barrier hypothesis, developed following the discovery that loss-of-function mutations in the gene encoding filaggrin - a key structural protein in the skin barrier - are a major genetic risk factor for atopic dermatitis. Filaggrin deficiency impairs the skin's ability to retain water and form an effective physical barrier, allowing allergens, irritants, and microorganisms to penetrate the skin and trigger immune activation.
This explains several clinical features:
Classic symptoms:
In infants and young children, eczema typically affects the face (cheeks), scalp, and extensor surfaces. The flexural pattern becomes more prominent from toddler age onward.
Weeping, crusting, and increased redness of eczema patches may indicate secondary infection with Staphylococcus aureus, a very common complication that requires antibiotic treatment alongside topical therapy.
Triggers do not cause eczema, but they precipitate flares. Identifying individual triggers through observation and modification is a core component of management:
Food allergies are more significant triggers in young children with eczema than in adults. In adults, food-triggered eczema flares are much less common and dietary restriction should only be undertaken if a clear temporal relationship is established, ideally under the guidance of an allergist or dietitian.
Emollients (moisturisers) are the cornerstone of eczema management. Evidence consistently shows that regular, generous moisturising reduces flare frequency, reduces the need for topical corticosteroids, and improves quality of life.
ASCIA and RACGP guidelines recommend:
Flare cycle
Good eczema care focuses on breaking the cycle and rebuilding the skin barrier.
Product selection matters: patients should trial different formulations to find one they will actually use consistently. An effective emollient that is used regularly is better than a theoretically superior one that the patient finds uncomfortable and uses infrequently.
Topical corticosteroids (TCS) are the most established and effective treatment for active eczema flares. The Pharmaceutical Benefits Scheme (PBS) lists a range of TCS formulations at different potency levels.
Understanding potency and appropriate site is more important than treating all steroid creams as the same medicine.
Key prescribing principles:
Common concerns about TCS relate to skin thinning (atrophy). This is primarily a risk with prolonged use of potent preparations on sensitive areas. Short courses as directed are safe, and the undertreatment of eczema flares carries its own risks (infection, sleep disruption, quality of life impact).
Topical calcineurin inhibitors - tacrolimus (Protopic) and pimecrolimus (Elidel) - are steroid-free anti-inflammatory treatments approved by the TGA for moderate-to-severe atopic dermatitis. They are particularly useful for:
Care routine
Most plans combine trigger reduction, regular moisturiser, and short targeted treatment during flares.
Both are Schedule 4 prescription medicines in Australia. A transient burning sensation on application is common when first used and typically resolves with continued use.
For moderate-to-severe eczema not adequately controlled with topical therapy, systemic treatments are available:
Dupilumab (Dupixent): A biologic (monoclonal antibody) targeting the IL-4/IL-13 pathway - key inflammatory mediators in atopic dermatitis. PBS-listed for moderate-to-severe atopic dermatitis in adults and adolescents (requires specialist initiation). Highly effective, with significant improvements in itch, skin clearance, and quality of life in clinical trials.
Baricitinib (Olumiant) and upadacitinib (Rinvoq): Oral JAK inhibitors PBS-listed for moderate-to-severe atopic dermatitis in adults. Provide rapid itch relief and skin clearance. Require specialist initiation and monitoring.
These treatments require specialist referral (dermatologist or clinical immunologist).
See your GP if:
Seek prompt care for:
Important warning
Good eczema care usually needs review rather than one-off treatment. A useful review checks whether the diagnosis still fits, whether the moisturiser routine is realistic, how often topical corticosteroids are being used, whether sleep is improving, and whether infection or contact dermatitis is contributing.
In-person assessment is preferable for a first diagnosis, uncertain rashes, suspected infection, severe flares, facial or eyelid involvement, widespread symptoms, or when specialist referral is being considered.
Safety boundary
Weeping, crusting, spreading redness, fever, or painful blisters need medical review before treating it as a routine flare.
Occasional reflux is common, but frequent heartburn, regurgitation, swallowing symptoms, chest pain, bleeding signs, or persistent vomiting need a more careful plan.
Stress and burnout overlap, but they are not the same. Learn the practical differences, common warning signs, workplace drivers, recovery steps, and when to seek professional support.
Conjunctivitis is common, but not every red eye is routine pink eye. Discharge, itch, contact lens use, pain, light sensitivity, and vision change determine the safest next step.